膀胱尿路上皮癌吡柔比星灌注化学疗法后的第2肿瘤1例

Second primary malignancy after pirubicin instillation chemotherapy for urothelial carcinoma of the bladder:A case report

非肌层浸润性膀胱癌(non-muscle-invasive bladder cancer,NMIBC)经尿道膀胱肿瘤切除(transurethral resection of bladder tumors,TUR-BT)术后复发及进展风险高,5年复发率高达30%~80%,术后原病理类型肿瘤复发相对常见,尿路上皮癌术后原位再发鳞状细胞癌病例罕见。接诊1例NMIBC尿路上皮癌患者,经TUR-BT术及吡柔比星灌注化学疗法后原位再发鳞状细胞癌,术后病理可见明显细胞间桥及角化珠。对膀胱尿路上皮癌吡柔比星灌注化学疗法后的第2肿瘤发生诱因、相关因素等进行分析,以供临床参考。

Non-muscle-invasive bladder cancer(NMIBC)has a high risk of recurrence and progression after transurethral resection of bladder tumors(TUR-BT).The recurrence rate in 5 years is as high as 30%to 80%.Recurrence of the primary pathologic tumor is common,but the secondary tumor in situ is rare.A patient with NMIBC urothelial carcinoma was diagnosed with in situ squamous cell carcinoma after TUR-BT and pirarubicin infusion chemotherapy.The postoperative pathology showed obvious intercellular bridge and keratinized beads.The cause of second tumor occurrence and related factors of bladder urothelial carcinoma after pirubicin infusion chemotherapy were analyzed for clinical reference.